$BRKR
BRUKER CORP

2024 Q4 Form 10-Q Financial Statement

#000095017024123298 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q4
Revenue $864.4M $854.5M
YoY Change 16.37% 20.62%
Cost Of Revenue $445.6M $424.2M
YoY Change 23.78% 23.75%
Gross Profit $418.8M $430.3M
YoY Change 9.4% 17.7%
Gross Profit Margin 48.45% 50.36%
Selling, General & Admin $229.9M $211.3M
YoY Change 29.45% 26.45%
% of Gross Profit 54.89% 49.11%
Research & Development $98.10M $83.40M
YoY Change 37.59% 31.34%
% of Gross Profit 23.42% 19.38%
Depreciation & Amortization $51.00M $37.30M
YoY Change 91.73% 52.24%
% of Gross Profit 12.18% 8.67%
Operating Expenses $350.7M $326.8M
YoY Change 35.77% 42.77%
Operating Profit $68.10M $103.5M
YoY Change -45.3% -24.29%
Interest Expense -$9.200M -$6.700M
YoY Change -335.9% -33.0%
% of Operating Profit -13.51% -6.47%
Other Income/Expense, Net -$12.80M $0.00
YoY Change 141.51%
Pretax Income $55.30M $240.9M
YoY Change -53.61% 99.09%
Income Tax $14.80M $37.10M
% Of Pretax Income 26.76% 15.4%
Net Earnings $40.90M $205.5M
YoY Change -53.58% 110.99%
Net Earnings / Revenue 4.73% 24.05%
Basic Earnings Per Share $0.27
Diluted Earnings Per Share $0.27 $1.41
COMMON SHARES
Basic Shares Outstanding 151.6M 151.4M 138.4M
Diluted Shares Outstanding 152.0

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $148.1M $488.3M
YoY Change -59.27% -24.35%
Cash & Equivalents $148.1M $488.3M
Short-Term Investments
Other Short-Term Assets $284.5M $216.4M
YoY Change 7.6% 11.83%
Inventory $1.220B $968.3M
Prepaid Expenses $35.60M $26.70M
Receivables $538.4M $492.0M
Other Receivables $66.80M $0.00
Total Short-Term Assets $2.191B $2.165B
YoY Change 7.98% 2.45%
LONG-TERM ASSETS
Property, Plant & Equipment $693.9M $599.7M
YoY Change 31.67% 23.14%
Goodwill $1.475B $582.6M
YoY Change 162.81% 27.32%
Intangibles $1.027B $330.5M
YoY Change 251.66% 22.0%
Long-Term Investments
YoY Change
Other Assets $238.1M $184.0M
YoY Change -41.96% 18.63%
Total Long-Term Assets $3.922B $2.074B
YoY Change 119.05% 38.38%
TOTAL ASSETS
Total Short-Term Assets $2.191B $2.165B
Total Long-Term Assets $3.922B $2.074B
Total Assets $6.113B $4.239B
YoY Change 60.04% 17.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $227.5M $202.7M
YoY Change 25.34% 13.62%
Accrued Expenses
YoY Change
Deferred Revenue $466.7M $400.0M
YoY Change 83.49%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $32.80M $121.2M
YoY Change -72.89% 548.13%
Total Short-Term Liabilities $1.322B $1.191B
YoY Change 23.3% 30.26%
LONG-TERM LIABILITIES
Long-Term Debt $2.265B $1.160B
YoY Change 106.13% -3.35%
Other Long-Term Liabilities $206.3M $474.2M
YoY Change -49.0% 185.32%
Total Long-Term Liabilities $2.471B $1.635B
YoY Change 64.38% 19.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.322B $1.191B
Total Long-Term Liabilities $2.471B $1.635B
Total Liabilities $4.270B $2.844B
YoY Change 65.79% 24.69%
SHAREHOLDERS EQUITY
Retained Earnings $2.401B $2.324B
YoY Change 20.65%
Common Stock $704.1M $282.9M
YoY Change 10.38%
Preferred Stock
YoY Change
Treasury Stock (at cost) $1.237B $1.237B
YoY Change 4.24% 14.03%
Treasury Stock Shares
Shareholders Equity $1.807B $1.395B
YoY Change
Total Liabilities & Shareholders Equity $6.113B $4.239B
YoY Change 60.04% 17.36%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q4
OPERATING ACTIVITIES
Net Income $40.90M $205.5M
YoY Change -53.58% 110.99%
Depreciation, Depletion And Amortization $51.00M $37.30M
YoY Change 91.73% 52.24%
Cash From Operating Activities $38.40M $205.5M
YoY Change -12.93% 19.83%
INVESTING ACTIVITIES
Capital Expenditures $32.60M $31.50M
YoY Change 21.19% -8.96%
Acquisitions
YoY Change
Other Investing Activities -$35.00M -$5.200M
YoY Change -72.68% -95.47%
Cash From Investing Activities -$67.60M -$36.70M
YoY Change -56.39% -75.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.700M -59.90M
YoY Change -97.08% 65.93%
NET CHANGE
Cash From Operating Activities 38.40M 205.5M
Cash From Investing Activities -67.60M -36.70M
Cash From Financing Activities -2.700M -59.90M
Net Change In Cash -31.90M 108.9M
YoY Change -84.32% -883.45%
FREE CASH FLOW
Cash From Operating Activities $38.40M $205.5M
Capital Expenditures $32.60M $31.50M
Free Cash Flow $5.800M $174.0M
YoY Change -66.28% 27.1%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001109354
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-30833
dei Entity Registrant Name
EntityRegistrantName
BRUKER CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3110160
dei Entity Address Address Line1
EntityAddressAddressLine1
40 Manning Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Billerica
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01821
dei City Area Code
CityAreaCode
978
dei Local Phone Number
LocalPhoneNumber
663-3660
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
BRKR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
151598240
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
148100000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
488300000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
538400000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
492000000
CY2024Q3 us-gaap Inventory Net
InventoryNet
1220400000
CY2023Q4 us-gaap Inventory Net
InventoryNet
968300000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
284500000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
215600000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
2191400000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
2164200000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
693900000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
599700000
CY2024Q3 us-gaap Goodwill
Goodwill
1474600000
CY2023Q4 us-gaap Goodwill
Goodwill
582600000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1026500000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
330500000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
147500000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
91700000
CY2024Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
340900000
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
297200000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
238100000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
184000000
CY2024Q3 us-gaap Assets
Assets
6112900000
CY2023Q4 us-gaap Assets
Assets
4249900000
CY2024Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
32800000
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
121200000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
227500000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
202700000
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
466700000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
400000000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
595100000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
478200000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1322100000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1202100000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2264500000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1160300000
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
94200000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
91500000
CY2024Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
178400000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
67700000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
120500000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
74800000
CY2024Q3 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
83800000
CY2023Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
76600000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
206300000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
163600000
CY2024Q3 us-gaap Liabilities
Liabilities
4269800000
CY2023Q4 us-gaap Liabilities
Liabilities
2836600000
CY2024Q3 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
18000000
CY2023Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
18700000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
260000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
260000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
182373563
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
175943705
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
151594684
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
145164826
CY2024Q3 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
1800000
CY2023Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
1700000
CY2024Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
30778879
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
30778879
CY2024Q3 us-gaap Treasury Stock Value
TreasuryStockValue
1237200000
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
1237200000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
704100000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
282900000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2400600000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2323800000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-62300000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
6000000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
1807000000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1377200000
CY2024Q3 us-gaap Minority Interest
MinorityInterest
18100000
CY2023Q4 us-gaap Minority Interest
MinorityInterest
17400000
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1825100000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1394600000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6112900000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4249900000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
864400000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
742800000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2386800000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2110000000
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
445600000
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
360000000
us-gaap Cost Of Revenue
CostOfRevenue
1230600000
us-gaap Cost Of Revenue
CostOfRevenue
1027000000
CY2024Q3 us-gaap Gross Profit
GrossProfit
418800000
CY2023Q3 us-gaap Gross Profit
GrossProfit
382800000
us-gaap Gross Profit
GrossProfit
1156200000
us-gaap Gross Profit
GrossProfit
1083000000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
229900000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
177600000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
646500000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
518200000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
98100000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
71300000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
272100000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
211300000
CY2024Q3 us-gaap Other Nonrecurring Expense
OtherNonrecurringExpense
22700000
CY2023Q3 us-gaap Other Nonrecurring Expense
OtherNonrecurringExpense
9400000
us-gaap Other Nonrecurring Expense
OtherNonrecurringExpense
56600000
us-gaap Other Nonrecurring Expense
OtherNonrecurringExpense
20100000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
350700000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
258300000
us-gaap Operating Expenses
OperatingExpenses
975200000
us-gaap Operating Expenses
OperatingExpenses
749600000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
68100000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
124500000
us-gaap Operating Income Loss
OperatingIncomeLoss
181000000
us-gaap Operating Income Loss
OperatingIncomeLoss
333400000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12800000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5300000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-30200000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-30100000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
55300000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
119200000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
150800000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
303300000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14800000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
30800000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
50700000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
80600000
CY2024Q3 brkr Equity In Income Losses Of Unconsolidated Investees Net Of Tax
EquityInIncomeLossesOfUnconsolidatedInvesteesNetOfTax
-200000
CY2023Q3 brkr Equity In Income Losses Of Unconsolidated Investees Net Of Tax
EquityInIncomeLossesOfUnconsolidatedInvesteesNetOfTax
300000
brkr Equity In Income Losses Of Unconsolidated Investees Net Of Tax
EquityInIncomeLossesOfUnconsolidatedInvesteesNetOfTax
-200000
brkr Equity In Income Losses Of Unconsolidated Investees Net Of Tax
EquityInIncomeLossesOfUnconsolidatedInvesteesNetOfTax
1200000
CY2024Q3 us-gaap Profit Loss
ProfitLoss
40300000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
88700000
us-gaap Profit Loss
ProfitLoss
99900000
us-gaap Profit Loss
ProfitLoss
223900000
CY2024Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-600000
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
600000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
500000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
2200000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
40900000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
88100000
us-gaap Net Income Loss
NetIncomeLoss
99400000
us-gaap Net Income Loss
NetIncomeLoss
221700000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.27
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.6
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.51
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.27
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.6
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.5
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
151.5
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146.6
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
148.1
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146.7
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
152
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147.3
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
148.7
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147.5
CY2024Q3 us-gaap Profit Loss
ProfitLoss
40300000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
88700000
us-gaap Profit Loss
ProfitLoss
99900000
us-gaap Profit Loss
ProfitLoss
223900000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
2300000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-100000
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
100000
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-900000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
67100000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-52200000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-39000000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-16100000
CY2024Q3 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsTax
26100000
CY2023Q3 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsTax
-6700000
us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsTax
9300000
us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsTax
1600000
CY2024Q3 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax Parent
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTaxParent
-83400000
CY2023Q3 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax Parent
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTaxParent
21500000
us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax Parent
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTaxParent
-28800000
us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax Parent
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTaxParent
-5100000
CY2024Q3 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
100000
CY2023Q3 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
0
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
100000
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
-600000
CY2024Q3 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
700000
CY2023Q3 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
200000
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-800000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-17000000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-30700000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-68000000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-20400000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
23300000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
58000000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
31900000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
203500000
CY2024Q3 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
300000
CY2023Q3 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
300000
us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
1600000
us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
2900000
CY2024Q3 brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
400000
CY2023Q3 brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
-800000
brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
-800000
brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
-1100000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
22600000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
58500000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
31100000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
201700000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1394600000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3400000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4600000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
200000
CY2024Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.05
CY2024Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
7300000
CY2024Q1 brkr Loans To Noncontrolling Interest
LoansToNoncontrollingInterest
900000
CY2024Q1 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
52300000
CY2024Q1 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
-14000000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1432900000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
500000
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-100000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4800000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2100000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
403000000
CY2024Q2 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.05
CY2024Q2 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
7700000
CY2024Q2 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
7900000
CY2024Q2 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
-36400000
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1807000000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
400000
CY2024Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-3200000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5200000
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
400000
CY2024Q3 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.05
CY2024Q3 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
7600000
CY2024Q3 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
40500000
CY2024Q3 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
-17600000
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1825100000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1125700000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
700000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-100000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4100000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
200000
CY2023Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
22300000
CY2023Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.05
CY2023Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
7400000
CY2023Q1 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
5300000
CY2023Q1 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
77500000
CY2023Q1 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
15100000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1198800000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
500000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4100000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1800000
CY2023Q2 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.05
CY2023Q2 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
7400000
CY2023Q2 brkr Loans To Noncontrolling Interest
LoansToNoncontrollingInterest
300000
CY2023Q2 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
58200000
CY2023Q2 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
-5000000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1250700000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5200000
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-3200000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4600000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
200000
CY2023Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
80300000
CY2023Q3 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.05
CY2023Q3 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
7400000
CY2023Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
1500000
CY2023Q3 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
89100000
CY2023Q3 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
-30300000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1227100000
us-gaap Profit Loss
ProfitLoss
99900000
us-gaap Profit Loss
ProfitLoss
223900000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
130900000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
77600000
us-gaap Share Based Compensation
ShareBasedCompensation
18500000
us-gaap Share Based Compensation
ShareBasedCompensation
17800000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-44200000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
12800000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
27500000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
19500000
us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
0
us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
6800000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2500000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
9400000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
4600000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-18300000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10700000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12400000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
105100000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
147300000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
26500000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
11100000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-17400000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-13500000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-49300000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
6500000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
34600000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
53500000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
61300000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
144600000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
78600000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
75400000
brkr Proceeds From Disposal Of Minority Investment
ProceedsFromDisposalOfMinorityInvestment
0
brkr Proceeds From Disposal Of Minority Investment
ProceedsFromDisposalOfMinorityInvestment
-11800000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
46000000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
19300000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
1576700000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
222300000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
900000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
10900000
us-gaap Payments For Proceeds From Hedge Investing Activities
PaymentsForProceedsFromHedgeInvestingActivities
-3700000
us-gaap Payments For Proceeds From Hedge Investing Activities
PaymentsForProceedsFromHedgeInvestingActivities
-5100000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1696700000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-289200000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
988600000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
1073400000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0
us-gaap Proceeds From Repayments Of Other Debt
ProceedsFromRepaymentsOfOtherDebt
-16500000
us-gaap Proceeds From Repayments Of Other Debt
ProceedsFromRepaymentsOfOtherDebt
-7000000
brkr Proceeds From2024 Note Purchase Agreements
ProceedsFrom2024NotePurchaseAgreements
472100000
brkr Proceeds From2024 Note Purchase Agreements
ProceedsFrom2024NotePurchaseAgreements
0
brkr Proceeds From2024 Term Loan Agreements
ProceedsFrom2024TermLoanAgreements
495600000
brkr Proceeds From2024 Term Loan Agreements
ProceedsFrom2024TermLoanAgreements
0
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
4800000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
3200000
brkr Repayment Of Two Thousand Twelve Notes Purchase Agreement
RepaymentOfTwoThousandTwelveNotesPurchaseAgreement
-100000000
brkr Repayment Of Two Thousand Twelve Notes Purchase Agreement
RepaymentOfTwoThousandTwelveNotesPurchaseAgreement
0
brkr Repayment Of Two Thousand Nineteen Notes Purchase Agreement
RepaymentOfTwoThousandNineteenNotesPurchaseAgreement
-11300000
brkr Repayment Of Two Thousand Nineteen Notes Purchase Agreement
RepaymentOfTwoThousandNineteenNotesPurchaseAgreement
-11300000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
5500000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
403000000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2800000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4800000
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
1400000
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
2700000
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
22600000
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
22100000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
101900000
us-gaap Proceeds From Payments To Minority Shareholders
ProceedsFromPaymentsToMinorityShareholders
-1000000
us-gaap Proceeds From Payments To Minority Shareholders
ProceedsFromPaymentsToMinorityShareholders
3500000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1304800000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-133500000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-9300000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-3700000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-339900000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-281800000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
491600000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
648700000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
151700000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
366900000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3300000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3200000
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3600000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3300000
us-gaap Nature Of Operations
NatureOfOperations
<div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Description of Business</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Bruker Corporation, together with its consolidated subsidiaries (“Bruker” or the “Company”), develops, manufactures and distributes high-performance scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular and cellular levels. Many of the Company’s products are used to detect, measure and visualize structural characteristics of chemical, biological and industrial material samples. The Company’s products address the rapidly evolving needs of a diverse array of customers in life science research, pharmaceuticals, biotechnology, applied markets, cell biology, clinical research, microbiology, in-vitro diagnostics, nanotechnology and materials science research.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">four</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable segments, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID (Chemicals, Applied Markets, Life Science, In Vitro Diagnostics, Detection), BSI NANO and Bruker Energy &amp; Supercon Technologies (BEST).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BSI BioSpin Segment designs, manufactures and distributes enabling life science tools based on magnetic resonance technology and provides laboratory automation and quality control workflow solutions in a wide range of chemical research fields. BSI BioSpin Segment’s revenues are generated by academic and government research customers, pharmaceutical and biotechnology companies and nonprofit laboratories, as well as chemical, food and beverage, clinical and other industrial companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BSI CALID Segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies, molecular diagnostics, microbiology and biomedical testing equipment, and radiological/nuclear detectors for Chemical, Biological, Radiological, Nuclear and Explosive (CBRNE) detection. Customers of the BSI CALID Segment include academic institutions and medical schools; pharmaceutical, biotechnology and diagnostics companies; contract research organizations; nonprofit and for-profit forensics laboratories; agriculture, food and beverage safety laboratories; environmental and clinical microbiology laboratories; hospitals and government departments and agencies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BSI NANO Segment designs, manufactures and distributes advanced X-ray instruments; atomic force microscopy instrumentation; advanced fluorescence optical microscopy instruments; analytical tools for electron microscopes and X-ray metrology; defect-detection equipment for semiconductor process control; handheld, portable and mobile X-ray fluorescence spectrometry instruments; spark optical emission spectroscopy systems; chipcytometry products and services for targeted spatial proteomics, multi-omic services; optofluidic and proteomic barcoding platforms; and products and services for spatial genomics research. Customers of the BSI NANO Segment include academic institutions, governmental customers, nanotechnology companies, semiconductor companies, raw material manufacturers, industrial companies, biotechnology and pharmaceutical companies and other businesses involved in materials research and life science research analysis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BEST Segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and “big science” research. The segment focuses on metallic low temperature superconductors for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research and other applications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The unaudited condensed consolidated financial statements represent the consolidated accounts of the Company. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements as of September 30, 2024, and December 31, 2023, and for the three and nine months ended September 30, 2024, and 2023, have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, the financial information presented herein does not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair statement have been included. The results for interim periods are not necessarily indicative of the results expected for any other interim period or the full year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Significant Accounting Policies</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s significant accounting policies as detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, continue to be applied at September 30, 2024. In addition, the Company has implemented two additional significant accounting policies as a result of activities that occurred in the quarter ended June 30, 2024:</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Multi-Currency Notional Cash Pooling Policy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective during the quarter ended June 30, 2024, the Company entered into a master netting arrangement with a third-party financial institution whereby certain subsidiaries participate in a notional cash pooling arrangement to manage global liquidity requirements. As part of the master netting arrangement, the participating subsidiaries combine their cash balances in pooling accounts at the same financial institution with the ability to offset bank overdrafts of one participant against positive cash account balances held by another participant. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amounts in each of the accounts are unencumbered and unrestricted with respect to use. At September 30, 2024, the net positive cash balance related to this pooling arrangement is included in cash, and cash equivalents in the consolidated balance sheets.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition Policy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">– Instrument rental and reagent agreements: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenues from instrument rental and reagent agreements provide customers with the right to use the Company’s instruments upon entering into multi-year agreements to purchase annual minimum amounts of reagents. These types of agreements include an embedded lease relating to the customer’s right to use the Company’s instruments over the period of the agreement. The agreement transaction price is allocated between the instrument and the reagents based on their relative standalone selling prices. When collectability of payments due is probable, reagent rental programs that effectively transfer control of instruments to customers are classified as sales-type leases and instrument revenue and cost of revenue are recognized upon the transfer of control to the customer which is often in advance of billings to the customer. The Company’s right to future consideration from reagent purchases under the agreement is allocated to instrument revenue and is recorded as a lease receivable within other current and long-term assets. Agreements that do not meet the criteria to be classified as a sales-type lease are classified as operating leases. Lease revenues from these agreements are presented in product revenue in the consolidated statements of income.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to the same risks and uncertainties as disclosed in its Annual Report on Form 10-K filed with the SEC on February 29, 2024.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the unaudited condensed consolidated financial statements requires the Company to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis the Company evaluates estimates, judgments and methodologies. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the global supply chain interruptions, higher energy costs and shortages, increased costs of and delivery times for critical raw materials, the global economy, including inflation and the threat of recession, and geopolitical instability will directly or indirectly impact future business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, research and development costs and employee cost related amounts, will depend on future developments that are highly uncertain, including as a result of new developments concerning global supply chain and various global conflicts. The Company has made estimates of the impact of these disruptions within the financial statements and there may be changes to those estimates in future periods. Actual results may differ from management’s estimates if these results differ from historical experience.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the unaudited condensed consolidated financial statements requires the Company to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis the Company evaluates estimates, judgments and methodologies. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the global supply chain interruptions, higher energy costs and shortages, increased costs of and delivery times for critical raw materials, the global economy, including inflation and the threat of recession, and geopolitical instability will directly or indirectly impact future business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, research and development costs and employee cost related amounts, will depend on future developments that are highly uncertain, including as a result of new developments concerning global supply chain and various global conflicts. The Company has made estimates of the impact of these disruptions within the financial statements and there may be changes to those estimates in future periods. Actual results may differ from management’s estimates if these results differ from historical experience.</span>
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
864400000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
742800000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2386800000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2110000000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
864400000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
742800000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2386800000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2110000000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
864400000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
742800000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2386800000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2110000000
CY2024Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
2207200000
CY2024Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
118000000
CY2023Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
85800000
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
560900000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
491400000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
466700000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
400000000
CY2023 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
294200000
CY2024Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
434300000
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
371200000
CY2024Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
402000000
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
314900000
CY2024Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
273300000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
183900000
CY2024Q3 us-gaap Other Inventory Demo
OtherInventoryDemo
110800000
CY2023Q4 us-gaap Other Inventory Demo
OtherInventoryDemo
98300000
CY2024Q3 us-gaap Inventory Net
InventoryNet
1220400000
CY2023Q4 us-gaap Inventory Net
InventoryNet
968300000
CY2024Q3 us-gaap Other Inventory In Transit
OtherInventoryInTransit
59300000
CY2023Q4 us-gaap Other Inventory In Transit
OtherInventoryInTransit
48600000
CY2024Q3 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
107700000
CY2023Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
82600000
CY2024Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
66800000
CY2023Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
45900000
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
35600000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
26700000
CY2024Q3 us-gaap Deposits Assets Current
DepositsAssetsCurrent
34300000
CY2023Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
28800000
CY2024Q3 us-gaap Asset Reporting Currency Denominated Value
AssetReportingCurrencyDenominatedValue
9000000
CY2023Q4 us-gaap Asset Reporting Currency Denominated Value
AssetReportingCurrencyDenominatedValue
12000000
CY2024Q3 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
31100000
CY2023Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
19600000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
284500000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
215600000
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
1627000000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
52100000
CY2024Q3 us-gaap Business Combination Contingent Consideration Asset
BusinessCombinationContingentConsiderationAsset
13400000
brkr Business Combination Consideration Transferred Working Capital Adjustment
BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment
-25200000
CY2024Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
57300000
CY2024Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
161200000
CY2024Q3 brkr Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets
27100000
CY2024Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
69900000
CY2024Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
82300000
CY2024Q3 us-gaap Deferred Taxes Business Combination Valuation Allowance Allocated To Contributed Capital
DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital
-117000000
CY2024Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
292000000
CY2024Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
1613500000
CY2024Q3 brkr Increase Decrease In Depreciation Depletion And Amortization
IncreaseDecreaseInDepreciationDepletionAndAmortization
-1800000
CY2023Q3 brkr Increase Decrease In Depreciation Depletion And Amortization
IncreaseDecreaseInDepreciationDepletionAndAmortization
9000000
brkr Increase Decrease In Depreciation Depletion And Amortization
IncreaseDecreaseInDepreciationDepletionAndAmortization
2400000
brkr Increase Decrease In Depreciation Depletion And Amortization
IncreaseDecreaseInDepreciationDepletionAndAmortization
34900000
CY2024Q3 us-gaap Interest Expense Interest Bearing Liability Increase Decrease
InterestExpenseInterestBearingLiabilityIncreaseDecrease
0
CY2023Q3 us-gaap Interest Expense Interest Bearing Liability Increase Decrease
InterestExpenseInterestBearingLiabilityIncreaseDecrease
10000000
us-gaap Interest Expense Interest Bearing Liability Increase Decrease
InterestExpenseInterestBearingLiabilityIncreaseDecrease
13300000
us-gaap Interest Expense Interest Bearing Liability Increase Decrease
InterestExpenseInterestBearingLiabilityIncreaseDecrease
30000000
CY2024Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
1800000
CY2023Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-19000000
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-15700000
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-64900000
us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
115400000
brkr Payments To Acquire Businesses Cash Acquired
PaymentsToAcquireBusinessesCashAcquired
107100000
us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
43800000
brkr Payments To Acquire Businesses Cash Acquired
PaymentsToAcquireBusinessesCashAcquired
23500000
CY2023Q4 us-gaap Goodwill
Goodwill
582600000
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
874000000
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
18000000
CY2024Q3 us-gaap Goodwill
Goodwill
1474600000
CY2024Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1453400000
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
426900000
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1026500000
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
686300000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
355800000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
330500000
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
28800000
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11500000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
70100000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
33400000
CY2024Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
3200000
CY2023Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
1300000
CY2024Q3 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
2278200000
CY2023Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
1260600000
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
2297300000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
1281500000
CY2024Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
32800000
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
121200000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2264500000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1160300000
CY2024Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
1058600000
CY2024Q3 us-gaap Line Of Credit
LineOfCredit
88800000
CY2024Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
158900000
CY2024Q3 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
810900000
CY2024Q3 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
1369900000
CY2023Q4 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
883300000
CY2024Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
230000000
CY2024Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
269000000
CY2024Q3 us-gaap Foreign Currency Contracts Liability Fair Value Disclosure
ForeignCurrencyContractsLiabilityFairValueDisclosure
0
CY2024Q3 us-gaap Derivative Notional Amount
DerivativeNotionalAmount
2771400000
CY2024Q3 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
-130700000
CY2023Q4 us-gaap Derivative Notional Amount
DerivativeNotionalAmount
1777900000
CY2023Q4 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
-89600000
CY2024Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-4700000
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1400000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-2700000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
9500000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14800000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
30800000
CY2024Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.268
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.258
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
50700000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
80600000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.336
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.266
CY2024Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
71700000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
58500000
CY2024Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
3900000
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
5800000
CY2024Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
400000
CY2023Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
200000
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
-1800000
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
800000
us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.058
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
40900000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
88100000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
99400000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
221700000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
151.5
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146.6
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
148.1
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146.7
CY2024Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0.5
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0.7
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0.6
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0.8
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
152
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147.3
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
148.7
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147.5
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.27
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.6
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.51
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.27
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.6
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.5
CY2022Q3 brkr Excise Tax On Stock Repurchases
ExciseTaxOnStockRepurchases
0.01
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5700000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4800000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15600000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13500000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5700000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4800000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15600000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13500000
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4900000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M6D
CY2024Q3 brkr Information Technology And Data Processing Cost Net
InformationTechnologyAndDataProcessingCostNet
2200000
CY2023Q3 brkr Information Technology And Data Processing Cost Net
InformationTechnologyAndDataProcessingCostNet
2200000
brkr Information Technology And Data Processing Cost Net
InformationTechnologyAndDataProcessingCostNet
4900000
brkr Information Technology And Data Processing Cost Net
InformationTechnologyAndDataProcessingCostNet
3300000
CY2024Q3 us-gaap Professional Fees
ProfessionalFees
9000000
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
200000
us-gaap Professional Fees
ProfessionalFees
10500000
us-gaap Professional Fees
ProfessionalFees
500000
CY2024Q3 brkr Restructuring Charges Excluding Cost Of Sales
RestructuringChargesExcludingCostOfSales
3100000
CY2023Q3 brkr Restructuring Charges Excluding Cost Of Sales
RestructuringChargesExcludingCostOfSales
3700000
brkr Restructuring Charges Excluding Cost Of Sales
RestructuringChargesExcludingCostOfSales
7800000
brkr Restructuring Charges Excluding Cost Of Sales
RestructuringChargesExcludingCostOfSales
4300000
CY2024Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
6800000
CY2023Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
1600000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
28400000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
7400000
CY2024Q3 brkr Other Miscellaneous Nonrecurring Expense
OtherMiscellaneousNonrecurringExpense
1600000
CY2023Q3 brkr Other Miscellaneous Nonrecurring Expense
OtherMiscellaneousNonrecurringExpense
1700000
brkr Other Miscellaneous Nonrecurring Expense
OtherMiscellaneousNonrecurringExpense
5000000
brkr Other Miscellaneous Nonrecurring Expense
OtherMiscellaneousNonrecurringExpense
4600000
CY2024Q3 us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
22700000
CY2023Q3 us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
9400000
us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
56600000
us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
20100000
CY2024Q3 us-gaap Restructuring Charges
RestructuringCharges
4300000
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
4800000
us-gaap Restructuring Charges
RestructuringCharges
17600000
us-gaap Restructuring Charges
RestructuringCharges
5700000
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
13100000
us-gaap Restructuring Charges
RestructuringCharges
17600000
us-gaap Payments For Restructuring
PaymentsForRestructuring
19600000
us-gaap Restructuring Reserve Translation And Other Adjustment
RestructuringReserveTranslationAndOtherAdjustment
-5600000
CY2024Q3 us-gaap Restructuring Reserve
RestructuringReserve
5500000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
1500000
CY2024Q3 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
0
CY2024Q3 brkr Scrapped Inventories
ScrappedInventories
4700000
brkr Scrapped Inventories
ScrappedInventories
4700000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1900000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000000
us-gaap Investment Income Interest
InvestmentIncomeInterest
6900000
us-gaap Investment Income Interest
InvestmentIncomeInterest
5300000
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
11600000
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
3900000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
32300000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
12000000
CY2024Q3 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
4400000
CY2023Q3 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
0
us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
24600000
us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
18300000
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
500000
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3300000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
18400000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-8800000
CY2024Q3 us-gaap Net Periodic Defined Benefits Expense Reversal Of Expense Excluding Service Cost Component
NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
-400000
CY2023Q3 us-gaap Net Periodic Defined Benefits Expense Reversal Of Expense Excluding Service Cost Component
NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
0
us-gaap Net Periodic Defined Benefits Expense Reversal Of Expense Excluding Service Cost Component
NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
-1000000
us-gaap Net Periodic Defined Benefits Expense Reversal Of Expense Excluding Service Cost Component
NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
100000
CY2024Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
400000
CY2023Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-100000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
400000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
3800000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12800000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5300000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-30200000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-30100000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
18400000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
68100000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
124500000
us-gaap Operating Income Loss
OperatingIncomeLoss
181000000
us-gaap Operating Income Loss
OperatingIncomeLoss
333400000
CY2024Q3 us-gaap Assets
Assets
6112900000
CY2023Q4 us-gaap Assets
Assets
4249900000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-123298-index-headers.html Edgar Link pending
0000950170-24-123298-index.html Edgar Link pending
0000950170-24-123298.txt Edgar Link pending
0000950170-24-123298-xbrl.zip Edgar Link pending
brkr-20240930.htm Edgar Link pending
brkr-20240930.xsd Edgar Link pending
brkr-ex31_1.htm Edgar Link pending
brkr-ex31_2.htm Edgar Link pending
brkr-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
brkr-20240930_htm.xml Edgar Link completed
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable